|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investments: | ||||||||||||||||||||
| Fixed maturity securities available for sale, at fair value (amortized cost: $1,523,005 in 2026; $1,227,605 in 2025) | ||||||||||||||||||||
| Equity securities, at fair value (cost: $109,595 in 2026; $81,772 in 2025) | ||||||||||||||||||||
| Equity method investment | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums receivable | ||||||||||||||||||||
| Deferred policy acquisition costs, net of ceding commissions and fronting fees | ||||||||||||||||||||
| Reinsurance recoverable on paid losses and loss adjustment expenses | ||||||||||||||||||||
| Reinsurance recoverable on unpaid losses and loss adjustment expenses | ||||||||||||||||||||
| Ceded unearned premiums | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Goodwill and intangible assets, net | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Accounts payable and other accrued liabilities | ||||||||||||||||||||
| Reserve for losses and loss adjustment expenses | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Ceded premium payable | ||||||||||||||||||||
| Funds held under reinsurance treaty | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Borrowings from credit agreements | ||||||||||||||||||||
| Term loan | ||||||||||||||||||||
| Deferred tax liabilities, net | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred stock, $0.0001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.0001 par value, 500,000,000 shares authorized, 26,186,979 and 26,520,417 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
